Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson’s Disease: A Protocol for a Randomized Controlled Trial
Abstract
:1. Introduction
2. Study Design and Aims
2.1. Study Design
2.2. Specific Aims
2.3. Ethics Approval and Informed Consent
2.4. Study Criteria
2.4.1. Inclusion Criteria
2.4.2. Exclusion Criteria
2.4.3. Withdrawal/Termination Criteria
2.5. Recruitment and Screening
2.6. Informed Consent
2.7. Randomization and Double-Blinding
3. Intervention
3.1. Experimental Group
3.2. Control Group
3.3. Adverse Events
4. Outcome Measures
4.1. Demographic and Clinical Information
4.2. Clinical Assessments
- Sleep quality will be measured using the Parkinson’s Disease Sleep Scale-2 (PDSS-2). This 15-item questionnaire addresses issues related to sleep quality, which has been shown to be reliable in identifying issues specific to PD [33]. A lower score indicates better sleep quality. The minimal clinically important difference (MCID) is the threshold of −3.44 points for detecting improvement or the threshold of 2.07 points for detecting worsening [34].
- Cognitive function will be assessed using standardized clinical testing methods. The Frontal Assessment Battery evaluates executive function including conceptualization, mental flexibility, programming, sensitivity to interference, inhibitory control, and environmental autonomy [35]. Its maximum score is 18. A higher score indicates better performance. The ten-point clock test will be used to evaluate cognitive deficits. In this test, participants will draw a round-faced clock with hands at ten past eleven. Scoring will be performed using the criteria by Manos and Wu (1994) [36]. The trail making test parts A and B will assess visual attention and task switching. In these tests, participants will connect a set of dots as quickly as possible. The completion time will be compared with normative data [37].
- Comprehensive non-motor symptoms in PD will be measured by the Parkinson’s Disease Non-Motor Symptom Questionnaire [38]. The assessment contains a total of 30 items including 10 domains (gastrointestinal tract symptoms, urinary tract symptoms, sexual function, cardiovascular symptoms, apathy/attention/memory, hallucinations/delusions, depression/anxiety/anhedonia, sleep/fatigue, pain, and miscellaneous (diplopia, weight loss, etc.)). A lower total score indicates milder PD symptoms.
- Fatigue level will be measured by the 16-item Parkinson Fatigue Scale, which has shown reasonably good reliability and validity in testing fatigue specific to PD [39]. Its maximum score is 90. A lower score indicates better symptoms.
- The severity of PD motor and non-motor symptoms will be assessed by the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale (UPDRS) [42]. This assessment consists of four parts including non-motor experiences of daily living (13 items), motor experiences of daily living (13 items), motor examination (18 items), and motor complications (6 items). A lower score indicates milder PD symptoms. The MCID is 2.5 points for detecting minimal improvement in the motor score and 4.3 points for observing minimal improvement in the total score [43].
- Quality of life will be evaluated using the 39-item Parkinson’s Disease Questionnaire [44]. This assessment covers eight dimensions, including mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. A lower score indicates better quality of life. The MCID of sub- and overall-scores suggested by Peto et al. (2001) will be utilized [45].
4.3. Serum Biomarkers
5. Sample Size Estimation, Statistical Methods, and Reporting Results
5.1. Sample Size Estimation
5.2. Statistical Analysis
5.3. Reporting Results
6. Discussion
Author Contributions
Funding
Conflicts of Interest
Appendix A
Date: | |
---|---|
Subject Name: | |
1. Assuming patient is available for answering questions, ask the following questions: | |
2. Are you able to participate in a study which requires the practice of mild daily exercise and about 11 visits to KU Medical Center over the course of 14 weeks? Specifically there will be 2 visits for assessment prior to and immediately following the study, 9 visits of group exercise sessions during the study. Will this work for you? YES—move onto question #3 NO—thank them for their time and let them know they are not eligible for this study at this time | |
3. Have you been diagnosed with primary (or idiopathic) Parkinson’s disease? YES—move onto next question NO—thank them for their time and let them know they are not eligible for this study at this time | |
4. Are you between the ages of 40 and 75? YES—move onto next question NO—thank them for their time and let them know they are not eligible for this study at this time | |
5. Treatments a) Are you aware of any intentions of changing your medication or dosages over the next three months? YES NO b) Does your treatment include Deep Brain Stimulation (DBS)? YES NO Part a) or Part b): YES—thank them for their time and let them know they are not eligible for this study at this time NO—move onto next question | |
6. Have you been diagnosed with any other medical problems (neurological, orthopedic, etc.) that interfere with your ability to do mild body movements and/or follow instructions? YES—thank them for their time and let them know they are not eligible for this study at this time NO—move onto next question | |
7. Are you able to give a simple blood test which includes 30ml (about 1 oz.) of venous blood collection at pre- and post-testing? YES—move onto next question NO—thank them for their time and let them know they are not eligible for this study at this time | |
8. Can you be contacted for participation in the study within two weeks? YES—move onto next question NO—When will you be available for the study ___________________ | |
9. What is the phone # and email address to contact you in the next three months? Cell phone # (if available): Email address: |
References
- Shulman, L.M.; Taback, R.L.; Rabinstein, A.A.; Weiner, W.J. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord. 2002, 8, 193–197. [Google Scholar] [CrossRef]
- Sullivan, K.L.; Ward, C.L.; Hauser, R.A.; Zesiewicz, T.A. Prevalence and treatment of non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord. 2007, 13, 545. [Google Scholar] [CrossRef] [PubMed]
- Schrag, A.; Jahanshahi, M.; Quinn, N. What contributes to quality of life in patients with Parkinson’s disease? J. Neurol. Neurosurg. Psychiatry 2000, 69, 308–312. [Google Scholar] [CrossRef] [PubMed]
- Chaudhuri, K.R.; Healy, D.G.; Schapira, A.H. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol. 2006, 5, 235–245. [Google Scholar] [CrossRef]
- Bonnet, A.M.; Jutras, M.F.; Czernecki, V.; Corvol, J.C.; Vidailhet, M. Nonmotor symptoms in Parkinson’s disease in 2012: Relevant clinical aspects. Parkinson’s Dis. 2012, 2012, 198316. [Google Scholar] [CrossRef]
- Tandberg, E.; Larsen, J.P.; Karlsen, K. A community-based study of sleep disorders in patients with Parkinson’s disease. Mov. Disord. 1998, 13, 895–899. [Google Scholar] [CrossRef] [PubMed]
- Diederich, N.J.; Vaillant, M.; Mancuso, G.; Lyen, P.; Tiete, J. Progressive sleep ‘destructuring’ in Parkinson’s disease. A polysomnographic study in 46 patients. Sleep. Med. 2005, 6, 313–318. [Google Scholar] [CrossRef]
- Sinforiani, E.; Zangaglia, R.; Manni, R.; Cristina, S.; Marchioni, E.; Nappi, G.; Mancini, F.; Pacchetti, C. REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson’s disease. Mov. Disord. 2006, 21, 462–466. [Google Scholar] [CrossRef]
- Postuma, R.B.; Gagnon, J.F.; Vendette, M.; Charland, K.; Montplaisir, J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov. Disord. 2008, 23, 1665–1672. [Google Scholar] [CrossRef]
- Greenamyre, J.T.; Hastings, T.G. Parkinson’s - Divergent causes, convergent mechanisms. Science 2004, 304, 1120–1122. [Google Scholar] [CrossRef]
- Smith, P.F. Inflammation in Parkinson’s disease: An update. Curr. Opin. Investig. Drugs 2008, 9, 478–484. [Google Scholar] [PubMed]
- Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Cytokines in Parkinson’s disease. J. Neural Transm. Suppl. 2000, 143–151. [Google Scholar]
- Reale, M.; Iarlori, C.; Thomas, A.; Gambi, D.; Perfetti, B.; Di Nicola, M.; Onofrj, M. Peripheral cytokines profile in Parkinson’s disease. Brain Behav. Immun. 2009, 23, 55–63. [Google Scholar] [CrossRef] [PubMed]
- Dufek, M.; Hamanova, M.; Lokaj, J.; Goldemund, D.; Rektorova, I.; Michalkova, Z.; Sheardova, K.; Rektor, I. Serum inflammatory biomarkers in Parkinson’s disease. Parkinsonism Relat. Disord. 2009, 15, 318–320. [Google Scholar] [CrossRef] [PubMed]
- Scalzo, P.; Kummer, A.; Cardoso, F.; Teixeira, A.L. Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neurosci. Lett. 2010, 468, 56–58. [Google Scholar] [CrossRef] [PubMed]
- Xiao, C.M.; Zhuang, Y.C. Effect of health Baduanjin Qigong for mild to moderate Parkinson’s disease. Geriatr. Gerontol. Int. 2016, 16, 911–919. [Google Scholar] [CrossRef] [PubMed]
- Wassom, D.J.; Lyons, K.E.; Pahwa, R.; Liu, W. Qigong exercise may improve sleep quality and gait performance in Parkinson’s disease: A pilot study. Int. J. Neurosci. 2015, 125, 578–584. [Google Scholar] [CrossRef]
- Moon, S.; Schmidt, M.; Smirnova, I.V.; Colgrove, Y.; Liu, W. Qigong exercise may reduce serum TNF-α levels and improve sleep in people with Parkinson’s disease: A pilot study. Medicines 2017, 4, 23. [Google Scholar] [CrossRef]
- Chin, A.; Svejda, B.; Gustafsson, B.I.; Granlund, A.B.; Sandvik, A.K.; Timberlake, A.; Sumpio, B.; Pfragner, R.; Modlin, I.M.; Kidd, M. The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302, G397–G405. [Google Scholar] [CrossRef] [Green Version]
- Baganz, N.L.; Blakely, R.D. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem. Neurosci. 2012, 4, 48–63. [Google Scholar] [CrossRef]
- Morgan, N.; Irwin, M.R.; Chung, M.; Wang, C. The effects of mind-body therapies on the immune system: Meta-analysis. PLoS ONE 2014, 9, e100903. [Google Scholar] [CrossRef] [PubMed]
- Manzaneque, J.M.; Vera, F.M.; Maldonado, E.F.; Carranque, G.; Cubero, V.M.; Morell, M.; Blanca, M.J. Assessment of immunological parameters following a qigong training program. Med. Sci. Monit. 2004, 10, Cr264–Cr270. [Google Scholar] [PubMed]
- Oh, B.; Butow, P.; Mullan, B.; Clarke, S.; Beale, P.; Pavlakis, N.; Kothe, E.; Lam, L.; Rosenthal, D. Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: A randomized controlled trial. Ann. Oncol. 2010, 21, 608–614. [Google Scholar] [CrossRef] [PubMed]
- Oh, B.; Butow, P.; Mullan, B.; Hale, A.; Lee, M.S.; Guo, X.; Clarke, S. A critical review of the effects of medical Qigong on quality of life, immune function, and survival in cancer patients. Integr. Cancer Ther. 2012, 11, 101–110. [Google Scholar] [CrossRef] [PubMed]
- Oh, B.; Butow, P.N.; Mullan, B.A.; Clarke, S.J.; Beale, P.J.; Pavlakis, N.; Lee, M.S.; Rosenthal, D.S.; Larkey, L.; Vardy, J. Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: A randomized controlled trial. Support. Care Cancer 2012, 20, 1235–1242. [Google Scholar] [CrossRef] [PubMed]
- Burini, D.; Farabollini, B.; Iacucci, S.; Rimatori, C.; Riccardi, G.; Capecci, M.; Provinciali, L.; Ceravolo, M. A randomised controlled cross-over trial of aerobic training versus Qigong in advanced Parkinson’s disease. Eur. Medicophys. 2006, 42, 231–238. [Google Scholar]
- Schmitz-Hubsch, T.; Pyfer, D.; Kielwein, K.; Fimmers, R.; Klockgether, T.; Wullner, U. Qigong exercise for the symptoms of Parkinson’s disease: A randomized, controlled pilot study. Mov. Disord. 2006, 21, 543–548. [Google Scholar] [CrossRef] [PubMed]
- Ventola, C.L. Current issues regarding Complementary and Alternative Medicine (CAM) in the United States: Part 1: The widespread use of CAM and the need for better-informed health care professionals to provide patient counseling. Pharm. Ther. 2010, 35, 461–468. [Google Scholar]
- ClinicalTrials.gov. Benefits of a mild body exercise in Parkinson’s disease. Available online: https://clinicaltrials.gov/ct2/show/NCT03463330 (accessed on 17 January 2019).
- Hughes, A.J.; Daniel, S.E.; Kilford, L.; Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55, 181–184. [Google Scholar] [CrossRef]
- Folstein, M.F.; Folstein, S.E.; McHugh, P.R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12, 189–198. [Google Scholar] [CrossRef]
- Bandura, A. Health promotion by social cognitive means. Health Educ. Behav. 2004, 31, 143–164. [Google Scholar] [CrossRef] [PubMed]
- Chaudhuri, K.R.; Pal, S.; DiMarco, A.; Whately-Smith, C.; Bridgman, K.; Mathew, R.; Pezzela, F.R.; Forbes, A.; Hogl, B.; Trenkwalder, C. The Parkinson’s disease sleep scale: A new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 2002, 73, 629–635. [Google Scholar] [CrossRef] [PubMed]
- Horváth, K.; Aschermann, Z.; Ács, P.; Deli, G.; Janszky, J.; Komoly, S.; Karádi, K.; Kovács, M.; Makkos, A.; Faludi, B. Minimal clinically important difference on Parkinson’s disease sleep scale 2nd version. Parkinson’s Dis. 2015, 2015, 970534. [Google Scholar] [CrossRef] [PubMed]
- Lima, C.F.; Meireles, L.P.; Fonseca, R.; Castro, S.L.; Garrett, C. The Frontal Assessment Battery (FAB) in Parkinson’s disease and correlations with formal measures of executive functioning. J. Neurol. 2008, 255, 1756–1761. [Google Scholar] [CrossRef] [PubMed]
- Manos, P.J.; Wu, R. The Ten Point Clock Test: A quick screen and grading method for cognitive impairment in medical and surgical patients. Int. J. Psychiatry Med. 1994, 24, 229–244. [Google Scholar] [CrossRef] [PubMed]
- Tombaugh, T.N. Trail Making Test A and B: Normative data stratified by age and education. Arch. Clin. Neuropsychol. 2004, 19, 203–214. [Google Scholar] [CrossRef] [Green Version]
- Chaudhuri, K.R.; Martinez-Martin, P.; Schapira, A.H.V.; Stocchi, F.; Sethi, K.; Odin, P.; Brown, R.G.; Koller, W.; Barone, P.; MacPhee, G.; et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: The NMSQuest study. Mov. Disord. 2006, 21, 916–923. [Google Scholar] [CrossRef] [PubMed]
- Brown, R.G.; Dittner, A.; Findley, L.; Wessely, S.C. The Parkinson fatigue scale. Parkinsonism Relat. Disord. 2005, 11, 49–55. [Google Scholar] [CrossRef] [PubMed]
- Yesavage, J.A.; Brink, T.L.; Rose, T. Geriatric Depression Scale (GDS); American Psychiatric Association: Washington, DC, USA, 2000. [Google Scholar] [CrossRef]
- Matheson, S.F.; Byrne, G.J.; Dissanayaka, N.N.; Pachana, N.A.; Mellick, G.D.; O’Sullivan, J.D.; Silburn, P.A.; Sellbach, A.; Marsh, R. Validity and reliability of the Geriatric Anxiety Inventory in Parkinson’s disease. Australas. J. Ageing 2012, 31, 13–16. [Google Scholar] [CrossRef] [PubMed]
- Goetz, C.G.; Tilley, B.C.; Shaftman, S.R.; Stebbins, G.T.; Fahn, S.; Martinez-Martin, P.; Poewe, W.; Sampaio, C.; Stern, M.B.; Dodel, R. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov. Disord. 2008, 23, 2129–2170. [Google Scholar] [CrossRef]
- Shulman, L.M.; Gruber-Baldini, A.L.; Anderson, K.E.; Fishman, P.S.; Reich, S.G.; Weiner, W.J. The clinically important difference on the unified Parkinson’s disease rating scale. Arch. Neurol. 2010, 67, 64–70. [Google Scholar] [CrossRef] [PubMed]
- Jenkinson, C.; Fitzpatrick, R.; Peto, V.; Greenhall, R.; Hyman, N. The Parkinson’s Disease Questionnaire (PDQ-39): Development and validation of a Parkinson’s disease summary index score. Age Ageing 1997, 26, 353–357. [Google Scholar] [CrossRef] [PubMed]
- Peto, V.; Jenkinson, C.; Fitzpatrick, R. Determining minimally important differences for the PDQ-39 Parkinson’s disease questionnaire. Age Ageing 2001, 30, 299–302. [Google Scholar] [CrossRef] [PubMed]
- Lee, M.S.; Lee, M.S.; Kim, H.J.; Moon, S.R. Qigong reduced blood pressure and catecholamine levels of patients with essential hypertension. Int. J. Neurosci. 2003, 113, 1691–1701. [Google Scholar] [CrossRef] [PubMed]
- Tsang, H.W.; Fung, K.M.; Chan, A.S.; Lee, G.; Chan, F. Effect of a Qigong exercise programme on elderly with depression. Int. J. Geriatr. Psychiatry 2006, 21, 890–897. [Google Scholar] [CrossRef] [PubMed]
- Tsang, H.W.; Mok, C.K.; Au Yeung, Y.T.; Chan, S.Y. The effect of Qigong on general and psychosocial health of elderly with chronic physical illnesses: A randomized clinical trial. Int. J. Geriatr. Psychiatry 2003, 18, 441–449. [Google Scholar] [CrossRef] [PubMed]
- Liu, W.; Zahner, L.; Cornell, M.; Le, T.; Ratner, J.; Wang, Y.; Pasnoor, M.; Dimachkie, M.; Barohn, R. Benefit of qigong exercise in patients with fibromyalgia: A pilot study. Int. J. Neurosci. 2012, 122, 657–664. [Google Scholar] [CrossRef]
- Clarke, T.C.; Black, L.I.; Stussman, B.J.; Barnes, P.M.; Nahin, R.L. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl. Health Stat. Rep. 2015, 79, 1–16. [Google Scholar]
Criteria | Rationale |
---|---|
Inclusion Criteria | |
Idiopathic PD | Individuals who had been diagnosed based on the United Kingdom Parkinson’s Disease Brain Bank Society diagnostic criteria are included to establish a diagnostic baseline. |
Women and men aged 40 to 75 years | Clinically, PD is not common in young individuals. In addition, individuals older than 75 years are more likely to have comorbidities or be on an advanced stage of PD, which may confound the study results. |
Current use of levodopa | Levodopa is a standard medication for PD. |
Stable levodopa dose | Changes in levodopa dosage may cause difficulties to determine whether the expected benefits are caused by the changed medication dose or the intervention. |
Hoehn and Yahr stage I to III | Hoehn and Yahr stage above III involves significant motor impairment, which may restrict individual’s movement during exercise. |
Exclusion Criteria | |
Mini Mental State Examination <24 | Less than score 24 on Mini Mental State Examination indicates cognitive impairment. Those individuals scored under 24 may have difficulties to follow study instructions. |
Other neurological disease including other forms of parkinsonism, uncontrolled or significant cardiovascular diseases, orthopedic or medical problems | Other neurological conditions may confound the study results. Uncontrolled or significant cardiovascular conditions and orthopedic conditions may cause unwanted events during the exercise. |
History of major head trauma with loss of consciousness | Qigong involves meditation. Individuals with head related injuries may have difficulties in meditation. |
Deep brain stimulation | It is possible that deep brain stimulation alters mechanisms of PD symptoms compared with those without deep brain stimulation, which may affect the study results. |
Expected change in PD medications or non-motor symptom medications (e.g., sleep, anxiety, and depression medications) | Changes in medication can induce changes in PD symptoms, which may confound the study findings. |
Abbreviation: PD, Parkinson’s disease. |
Movement | Sound | Body Movement and Breathing |
---|---|---|
Relaxation movement | No sound | When inhaling, lift up both arms/hands with elbows fully extended out from both sides with palms down. Lift arms to the shoulder level. Move both arms/hands horizontally to the front and then towards the chest. Exhale as arms/hands move down slowly until the end of exhalation. Repeat the breath and body movement three times. Perform this movement before Movement 1, between each movement, and after Movement 6 (a total of seven times throughout the exercise). |
Movement 1 | Hsu [shh] | When inhaling, lift up both arms/hands near the body to chest level, palms facing up. Then straighten the arms out to the sides. Then move the hands to the chest. Exhale as the arms/hands move down. During the slow exhalation, chant “shh”. Repeat the sound and movement six times. |
Movement 2 | Her [her] | When inhaling, lift up both arms/hands near the body to the chest level with the palms facing up. Begin to exhale. During exhalation, chant “her” and continue to slowly move arms/hands up to the eyebrow level. Inhale while moving arms/hands down. Convert to exhalation when hands pass the chest level and continue to move arms/hands down. Repeat the sound and movement six times. |
Movement 3 | Hoo [who] | When inhaling, lift up both arms/hands near the body to chest level, palms facing up. Then, begin to exhale and chant “who” while slowly moving your left hand up and right hand down in a diagonal direction until the end of exhalation. Inhale and move left hand down and right hand up to the chest level again. Convert to exhalation and chant “who” while slowly moving the left hand down and the right hand up in a diagonal direction until the end of exhalation. Repeat the sound and movement three times. |
Movement 4 | Sss [sss] | When inhaling, lift up both arms/hands to the chest level, palms facing up. Begin to exhale. During exhalation, chant “sss” while slowly pushing the hands forward and then down to both sides until the end of exhalation. Repeat the sound and movement six times. |
Movement 5 | Chway [ch-way] | When inhaling, lift up both arms/hands through the back of trunk to the front of the chest as if holding a large ball. Begin to exhale. During exhalation, chant “chway” while slowly moving both hands out over and down an imaginary ball until touching the thighs. (Bend both knees down slightly while you circle your hands down over the ball). Repeat the sound and movement six times. |
Movement 6 | See [see] | When inhaling, lift up both arms/hands near the body to the chest level, palms facing up. Begin to exhale. During exhalation, chant “see” (with a smile on your face) and continue to slowly lift hands straight over the head until the end of exhalation. Begin to inhale while slowly moving returning arms/hands along the same path. Begin to exhale again when the hands pass over the chest and continue to move arms/hands down until the end of exhalation. Repeat the sound and movement six times. |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Moon, S.; Sarmento, C.V.M.; Smirnova, I.V.; Colgrove, Y.; Lyons, K.E.; Lai, S.M.; Liu, W. Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson’s Disease: A Protocol for a Randomized Controlled Trial. Medicines 2019, 6, 13. https://doi.org/10.3390/medicines6010013
Moon S, Sarmento CVM, Smirnova IV, Colgrove Y, Lyons KE, Lai SM, Liu W. Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson’s Disease: A Protocol for a Randomized Controlled Trial. Medicines. 2019; 6(1):13. https://doi.org/10.3390/medicines6010013
Chicago/Turabian StyleMoon, Sanghee, Caio V. M. Sarmento, Irina V. Smirnova, Yvonne Colgrove, Kelly E. Lyons, Sue M. Lai, and Wen Liu. 2019. "Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson’s Disease: A Protocol for a Randomized Controlled Trial" Medicines 6, no. 1: 13. https://doi.org/10.3390/medicines6010013
APA StyleMoon, S., Sarmento, C. V. M., Smirnova, I. V., Colgrove, Y., Lyons, K. E., Lai, S. M., & Liu, W. (2019). Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson’s Disease: A Protocol for a Randomized Controlled Trial. Medicines, 6(1), 13. https://doi.org/10.3390/medicines6010013